Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2300544 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Anabel Zwick und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Virology, Saarland University Medical Center, Homburg, Germany. Hauptthemen laut MEDLINE: Neutrophils, ErbB Receptors, Antibody-Dependent Cell Cytotoxicity, Protein Engineering. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: German Research Foundation (DFG), Saarland University.
Abstract (Originalsprache)
Human IgA Abs engage neutrophils for cancer immunotherapy more effectively than IgG Abs. Previous studies demonstrated that engineering approaches improved biochemical and functional properties. In this study, we report a novel, to our knowledge, IgA2 Ab against the epidermal growth factor receptor generated by protein engineering and polymerization. The resulting molecule demonstrated a covalent linkage of L and H chains and an effective polymerization by the joining chain. The engineered dimer outperformed its monomeric variant in functional experiments on Fab-mediated modes of action and binding to the Fc receptor. The capacity to engage neutrophils for Ab-dependent cell-mediated cytotoxicity (ADCC) of adherent growing target cancer cells was cell line dependent. Although the engineered dimer displayed a long-term efficacy against the vulva carcinoma cell line A431, there was a notable in-efficacy against human papillomavirus (HPV)− head and neck squamous cell carcinoma (HNSCC) cell lines. However, the highly engineered IgA Abs triggered a neutrophil-mediated cytotoxicity against HPV+ HNSCC cell lines. Short-term ADCC efficacy correlated with the target cells’ epidermal growth factor receptor expression and the ability of cancer cell–conditioned media to enhance the CD147 surface level on neutrophils. Notably, the HPV+ HNSCC cell lines demonstrated a significant increment in releasing soluble CD147 and a reduced induction of membranous CD147 on neutrophils compared with HPV− cells. Although membranous CD147 on neutrophils may impair proper IgA–Fc receptor binding, soluble CD147 enhanced the IgA–neutrophil-mediated ADCC in a dose-dependent manner. Thus, engineering IgA Abs and impedance-based ADCC assays provided valuable information regarding the target–effector cell interaction and identified CD147 as a putative critical parameter for neutrophil-mediated cytotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Virology, Saarland University Medical Center, Homburg, Germany.
- Department of Otorhinolaryngology, Head and Neck Surgery; Saarland University Medical Center, Homburg/Saar, Germany.
ORCID-Profile: Felix Leon Braun, Lennert Jochen Weber, Manuel Linder, Maximilian Linxweiler, Stefan Lohse
Förderung
- German Research Foundation (DFG)
- Saarland University
Zitieren
APA
Zwick, A., Braun, F. L., Weber, L. J., Linder, M., Linxweiler, M., & Lohse, S. (2024). Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300544
Vancouver
Zwick A, Braun FL, Weber LJ, Linder M, Linxweiler M, Lohse S. Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300544
BibTeX
@article{Zwick2024,
author = {Zwick, Anabel and Braun, Felix Leon and Weber, Lennert Jochen and Linder, Manuel and Linxweiler, Maximilian and Lohse, Stefan},
title = {Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2300544}
}
EUVIMED